Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type ...
Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, ...
Myeloproliferative neoplasms (MPNs) represent a cluster of conditions characterized by the excessive production of blood cells within the bone marrow. Among MPN patients, abnormal quantities of red ...
The JAK2 gene mutation discovery led to JAK inhibitors, transforming myelofibrosis treatment by targeting the JAK-STAT pathway. Four FDA-approved JAK inhibitors for myelofibrosis include Jakafi, ...
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...
Concurrent ET and WM in a patient highlights challenges in managing coexisting myeloproliferative and lymphoplasmacytic malignancies. Distinct genetic mutations in the patient suggest independent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback